BBlogFlow

Changing the COPD Narrative: Interview with David Mannino - EMJ

·1h ago

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

David Mannino | Professor, University of Kentucky College of Medicine, Lexington, USA; Chief Medical Officer, COPD Foundation

Could you tell us what first drew you to respiratory medicine and COPD, and how this interest has developed throughout your career?

This article is an excerpt. To read the full content, visit the original source. EMJ

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

COPD Is a Modifiable Disease: Highlights from ERS 2026 - EMJ

Conflicts of interest: Carlin has received conference travel, speaker fees, advisory board, unrestricted investigator-initiated grant, and joint working support from AstraZeneca, Glaxo-Smith Kline, Sanofi-Regeneron, and ResMed. Keywords: Case-finding, COPD, diagnosis, exacerbations, lung cancer screening.

EMJ·

Examining the Oral Steroid Burden in Asthma and COPD - HCPLive

Patients with asthma and chronic obstructive pulmonary disease (COPD) often receive systemic corticosteroids from multiple specialties, and that cumulative exposure is rarely tracked in 1 place. At the same time, the options for reducing reliance on oral steroids have grown, with approvals of dupilumab and mepolizumab for eosinophilic COPD and of depemokimab, a twice-yearly anti-interleukin (IL)-5 agent, for severe asthma.1-4 Clinicians outside pulmonology increasingly manage these patients when specialty access is limited. On October 6, 2026, Mollie Chartoff, FNP-BC, a nurse practitioner on the advanced COPD team at Vanderbilt Lung Institute in Nashville, Tennessee, moderated a virtual clinical forum for advanced practice providers on asthma and COPD. Participants included nurse practitioners and physician assistants in pulmonology, allergy and asthma, dermatology, oncology, and interventional pain practices in Tennessee, Texas, Missouri, and North Carolina. The discussion covered biomarkers, oral corticosteroid (OCS) exposure, biologic selection, and access barriers.

HCPLive·

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD - HCPLive

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment. Arguing the pro side of a debate at the American College of Chest Physicians (CHEST) 2026 Annual Meeting in Phoenix, Omid Pourshahid, MD, MPH, FCCP, Medical Director, Pulmonary Rehabilitation, Temple University Hospital, said pulmonary rehabilitation should be tailored to each patient’s clinical status and barriers to care rather than delivered through a single center-based model.¹The position builds on a long-standing gap in pulmonary rehabilitation uptake. In a retrospective cohort of 197,376 Medicare beneficiaries hospitalized for COPD in 2014, only 2721 (1.5%) initiated pulmonary rehabilitation within 90 days of discharge.² Initiation within the 90-day window was associated with a lower risk of death at 1 year (hazard ratio [HR], 0.63; 95% CI, 0.57-0.69; P <.001).

HCPLive·